Pharmaron, a CRO offering lab and manufacturing services, has acquired Quotient Bioresearch, a UK-based CRO focused on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.

The acquisition expands Pharmaron’s technology platforms in chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development, and strengthens its service portfolio with more comprehensive services. Also, the combined company will generate greater market access in Asia, Europe and the U.S.

“We are very pleased to have Quotient Bioresearch join the Pharmaron team,” said Dr. Boliang Lou, chief executive officer of Pharmaron. “This acquisition is part of our long-term strategy to grow our services and broaden our technical and geographic footprint to better serve clients throughout the world. Combining these two companies gives Pharmaron industry-leading custom radiosynthesis capabilities, and further consolidates our leading position in the field of discovery, pre-clinical and clinical DMPK. This move will help accelerate the discovery and development of novel drugs for our customers with Pharmaron’s comprehensive and integrated drug research and development engine.”

Stephen Lewinton, managing director of Quotient, said, “Quotient is focused on radiosynthesis and regulatory DMPK, particularly human clinical metabolism while Pharmaron has premier expertise in drug R&D services including discovery and pre-clinical safety and early phase DMPK. We are excited to become part of Pharmaron’s integrated drug research and development platform.”